O
O. Ataman
Researcher at Eisai
Publications - 8
Citations - 545
O. Ataman is an academic researcher from Eisai. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 6, co-authored 8 publications receiving 440 citations. Previous affiliations of O. Ataman include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Clinical development of new drug-radiotherapy combinations
Ricky A. Sharma,Ruth Plummer,Julie K Stock,Tessa A Greenhalgh,O. Ataman,Stephen Kelly,Robert Clay,Richard Adams,Richard D. Baird,Lucinda Billingham,Sarah Brown,Sean Buckland,Helen Bulbeck,Anthony J. Chalmers,Glen Clack,Aaron N Cranston,Lars Damstrup,Roberta Ferraldeschi,Martin Forster,Golec Julian M C,Russell M Hagan,Emma Hall,Axel-R Hanauske,Kevin J. Harrington,Tom Haswell,Maria A. Hawkins,Timothy M Illidge,Hazel Jones,Andrew S. Kennedy,Fiona McDonald,Thorsten Melcher,James P B O'Connor,John Pollard,Mark P Saunders,David Sebag-Montefiore,Melanie Smitt,John Staffurth,Ian J. Stratford,Stephen R. Wedge +38 more
TL;DR: The CTRad Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer are highlighted.
Journal ArticleDOI
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status
Glenwood D. Goss,David Ferry,Rafal Wierzbicki,Scott A. Laurie,Joyce Thompson,Bonne Biesma,Fred R. Hirsch,Marileila Varella-Garcia,Emma Duffield,O. Ataman,Marc Zarenda,Alison Armour +11 more
TL;DR: There was no statistically significant difference in PFS, OS, and ORRs after treatment with gefitinib or placebo, in the overall population; improvements in QOL and symptoms were similar in both groups.
Journal ArticleDOI
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
D. S. Boss,Petronella O. Witteveen,J. van der Sar,M. P. Lolkema,Emile E. Voest,Paul K. Stockman,O. Ataman,David Wilson,Shampa Das,Jan H.M. Schellens +9 more
TL;DR: AZD1152 was generally well tolerated with neutropenia being the most frequently reported AE and DLT and no objective tumor responses were observed at any dose or schedule, although stable disease, as defined by RECIST, was achieved in 15 patients overall.
Journal ArticleDOI
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz,Richard D. Carvajal,Rachel Midgley,Scott J. Rodig,Paul K. Stockman,O. Ataman,David Wilson,Shampa Das,Geoffrey I. Shapiro +8 more
TL;DR: In this article, the maximum tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase, was determined.
Journal ArticleDOI
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.
David S. Hong,Aparna Raj Parikh,Geoffrey I. Shapiro,Andrea Varga,Aung Naing,Funda Meric-Bernstam,O. Ataman,Larisa Reyderman,Terri A. Binder,Min Ren,Mingjie Liu,Satish Dayal,Amy Siu,Pallavi Sachdev,Lucy Xu,Vijay Bhagawati-Prasad,Ilian Tchakov,Chean Eng Ooi,Xingfeng Bao,Aurélien Marabelle +19 more
TL;DR: In this first-in-human phase 1 study, E7046 administered orally once daily demonstrated manageable tolerability, immunomodulatory effects, and a best response of stable disease in several heavily pretreated patients with advanced malignancies.